tradingkey.logo
搜尋

Transmedics Group Inc

TMDX
添加自選
67.850USD
+1.430+2.15%
收盤 07/01, 16:00美東報價延遲15分鐘
2.34B總市值
13.44本益比TTM

Transmedics Group Inc

67.850
+1.430+2.15%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.15%

5天

-8.10%

1月

+0.97%

6月

-44.23%

今年開始到現在

-44.23%

1年

-49.37%

關鍵數據
67.680今開
71.670最高
1.06M成交量
13.44本益比TTM
17.23本益比動
--股利TTM
3.06%換手率
66.420昨收
67.440最低
54.50M成交額
66.09本益比靜
4.74市淨率
0.00%股息率 TTM
15.13%ROA
156.00052週最高
0.64量比
35.46M淨利潤
34.55M總股本
5.0490每股盈餘TTM
1.94Beta
45.22%ROE
60.10552週最低
6.37%振幅
58.16%毛利率
2.34B總市值
-0.94回報/風險
3.17%風險率

TradingKey Transmedics Group Inc股票評分

單位: USD 更新時間: 2026-06-30

操作建議

Transmedics Group Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名55/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為123.10。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Transmedics Group Inc評分

相關信息

行業排名
55 / 204
全市場排名
131 / 4569
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Transmedics Group Inc亮點

亮點風險
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
業績高增長
公司營業收入穩步增長,連續3年增長150.59%
估值合理
公司最新PE估值13.16,處於3年歷史合理位
機構減倉
最新機構持股42.29M股,環比減少3.95%
約翰·胡斯曼持倉
明星投資者約翰·胡斯曼持倉,最新持倉44.62K股

分析師目標

基於 13 分析師
買入
評級
123.100
目標均價
+85.34%
漲幅空間

Transmedics Group Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Transmedics Group Inc簡介

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
公司代碼TMDX
公司Transmedics Group Inc
CEOHassanein (Waleed H)
網址https://www.transmedics.com/

常見問題

Transmedics Group Inc(TMDX)的當前股價是多少?

Transmedics Group Inc(TMDX)的當前股價是 66.42。

Transmedics Group Inc 的股票代碼是什麼?

Transmedics Group Inc的股票代碼是TMDX。

Transmedics Group Inc股票的52週最高點是多少?

Transmedics Group Inc股票的52週最高點是156.00。

Transmedics Group Inc股票的52週最低點是多少?

Transmedics Group Inc股票的52週最低點是60.10。

Transmedics Group Inc的市值是多少?

Transmedics Group Inc的市值是2.30B。

現在Transmedics Group Inc(TMDX)的股票是買入、持有還是賣出?

根據分析師評級,Transmedics Group Inc(TMDX)的總體評級為買入,目標價格為123.10。

Transmedics Group Inc(TMDX)股票的每股收益(EPS TTM)是多少

Transmedics Group Inc(TMDX)股票的每股收益(EPS TTM)是5.60。